Investment Rating - The report gives a "Buy" rating for the company, with a target price of HKD 90.5, compared to the current price of HKD 69.60 [3][8]. Core Insights - The company is a leading provider of invisible orthodontics in China, having surpassed competitors in market share since 2021, and is experiencing robust growth in overseas markets, with a significant increase in case numbers and revenue [1][19]. - The domestic market for invisible orthodontics has substantial growth potential, with penetration rates expected to rise significantly in the coming years, particularly in the youth and grassroots markets [7][52]. - The company has established a strong competitive advantage through product innovation, a robust supply chain, and effective marketing strategies, which have facilitated its expansion into international markets [2][11]. Summary by Sections Section 1: Company Overview - The company has been a key player in the invisible orthodontics sector for over 20 years, achieving the top market position in China since 2021, with over 40% market share [28][19]. - The company has expanded internationally, acquiring a majority stake in a Brazilian orthodontic manufacturer, and has seen overseas case numbers surpass domestic ones by 2025H1 [16][19]. Section 2: Domestic Business Growth Potential - The domestic invisible orthodontics market is under pressure but has significant room for growth, with penetration rates expected to increase from 16% in 2024 to 25% by 2030 [46][52]. - The market is experiencing a consolidation trend, with leading companies benefiting from increased market concentration as smaller players exit due to competitive pressures [56][31]. Section 3: International Expansion Potential - The global market for invisible orthodontics is several times larger than the domestic market, providing substantial growth opportunities for the company [11][19]. - The company has improved its global market share from 4.5% in 2022 to an estimated 10.1% in 2025, with expectations to reach over 20% in the future [2][11]. - Revenue from overseas operations is projected to grow significantly, with estimates of USD 1.6 billion by 2033, driven by increased market penetration and operational efficiencies [11][12]. Section 4: Financial Projections and Valuation - The company is expected to generate total revenues of USD 337 million, USD 412 million, and USD 495 million for the years 2025, 2026, and 2027, respectively, with net profits projected at USD 27 million, USD 22 million, and USD 41 million [3][12]. - The report employs a price-to-sales (P/S) valuation method, estimating a P/S ratio of 4.8X for 2026, leading to a target market capitalization of HKD 154.5 billion [8][12].

Investment Rating - The report assigns a "Buy" rating to the company for the first time [8]. Core Insights - The company is a leading provider of invisible orthodontics in China, having surpassed competitors in domestic market share since 2021, and is experiencing rapid growth in overseas markets [1][28]. - The global invisible orthodontics market presents significant growth opportunities, with the company expected to increase its market share from 10% to over 20% in the coming years [2][11]. - The company’s revenue is projected to grow significantly, with total revenues expected to reach approximately $495 million by 2027, reflecting a compound annual growth rate (CAGR) of 20.4% [3][12]. Summary by Sections Section 1: Company Overview - The company has been a key player in the invisible orthodontics sector for over 20 years, achieving the top market position in China since 2021 [16][28]. - The company has expanded internationally, acquiring a majority stake in a Brazilian orthodontic manufacturer, which has contributed to its overseas case numbers exceeding domestic figures by 2025 [16][19]. Section 2: Domestic Business Growth Potential - The domestic market for invisible orthodontics has substantial growth potential, with penetration rates expected to rise from 16% in 2024 to 25% by 2030 [7][46]. - The market is experiencing consolidation, with leading companies benefiting from increased market concentration as smaller competitors exit due to pricing pressures [10][56]. Section 3: International Expansion Potential - The company’s global market share has increased from 4.5% in 2022 to 10.1% in 2025, with expectations to reach over 20% in the future [2][11]. - The company has established a comprehensive competitive advantage through product innovation, supply chain efficiency, and targeted marketing strategies [2][11]. Section 4: Financial Projections and Valuation - Revenue forecasts for 2025, 2026, and 2027 are $337 million, $412 million, and $495 million respectively, with net profits projected at $27 million, $22 million, and $41 million [3][12]. - The report utilizes a price-to-sales (P/S) valuation method, estimating a target market capitalization of HKD 154.5 billion and a target share price of HKD 90.5 [8][12].

Investment Rating - The investment rating for JD Health (6618.HK) is "Buy" (maintained) [1][9] Core Views - JD Health reported strong revenue and profit growth for 2025, with revenue reaching 73.4 billion RMB, a year-on-year increase of 26.3%. Adjusted operating profit was 4.39 billion RMB, up 69% year-on-year, and adjusted net profit was 6.53 billion RMB, a 36% increase [4][5] - The company is actively building a new infrastructure for "AI + supply chain" in healthcare, enhancing its competitive edge in the pharmaceutical supply chain and the synergy between self-operated and platform services [5][8] Financial Performance - In 2025, revenue from pharmaceutical and health products grew by 25% to 60.9 billion RMB, while revenue from online platforms/digital marketing and other services increased by 34% to 12.6 billion RMB [5] - The annual active user count reached 218 million by December 31, 2025, with a net increase of over 34 million users compared to 2024 [5] - As of December 31, 2025, the company's total cash reserves amounted to 69.5 billion RMB [5] Business Development - JD Health launched over 100 new drugs in 2025, significantly increasing from over 30 in 2024, aiming to become the "first stop for new drug launches" [5] - The company has over 7,000 health supplement brands that have seen continuous sales growth for three consecutive years, focusing on high-potential categories such as infant development and anti-aging [5] - The instant retail business is rapidly developing, with over 300 self-operated pharmacy stores opened, and the JD Home Health Check service saw an 81.9% increase in order volume in 2025 [5][8] Future Projections - Revenue projections for 2026-2028 are 87.4 billion RMB, 100.4 billion RMB, and 112.2 billion RMB, respectively, with adjusted net profits of 6.64 billion RMB, 7.48 billion RMB, and 8.21 billion RMB [7][8] - The company is expected to benefit from the increasing online penetration of pharmaceuticals and the expansion of online medical insurance payment services [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company has entered a phase of "structural optimization and profit recovery," with an increase in the proportion of self-operated products and multi-channel layout expected to continue improving profitability [11] - The company reported a significant recovery in profitability, with a net profit of 239 million yuan in FY2026H1, compared to a loss of 96.5 million yuan in the same period last year [6][11] - The self-operated product strategy has become a core growth engine, contributing 2 billion yuan in revenue in FY2026H1, representing a year-on-year increase of 18.1% [8] Financial Performance Summary - For FY2026H1, the company achieved revenue of 2.31 billion yuan, a year-on-year increase of 5.7%, with GMV totaling approximately 4.1 billion yuan, reflecting a 16.4% growth after excluding one-time disturbances [6] - The gross profit for FY2026H1 was 840 million yuan, with a gross margin of 36.4%, an increase of 2.8 percentage points year-on-year, driven by an increase in the proportion of self-operated products and improved supply chain efficiency [6] - The company’s operating expenses have stabilized, with sales expense ratio, management expense ratio, and R&D expense ratio at approximately 19%, 3.6%, and 2.3% respectively, showing a significant decrease compared to the previous year [7] Future Projections - The company is projected to achieve revenues of 5.08 billion yuan, 6.05 billion yuan, and 7.19 billion yuan for FY2026, FY2027, and FY2028 respectively, with corresponding net profits of 445.26 million yuan, 528.04 million yuan, and 644.72 million yuan [10][11] - The expected P/E ratios for FY2026, FY2027, and FY2028 are approximately 50.14, 42.28, and 34.63 respectively, indicating a favorable valuation outlook [10][11]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company has demonstrated significant improvements in cost control and utilization rates, leading to an upward revision of its full-year revenue guidance [3][6] - For FY2026Q2, the company reported net revenue of $1.19 billion, exceeding the upper limit of its guidance by 2.4%, with a year-over-year growth of 14.7% [6] - The company has increased its full-year revenue forecast to $5.29 billion to $5.49 billion, reflecting a year-over-year growth of 8% to 12% [7][11] Financial Performance - In FY2026Q2, the company achieved a Non-GAAP operating profit of $89.13 million, a year-over-year increase of 206.9%, with a Non-GAAP operating profit margin of 7.5%, up 4.7 percentage points [6] - The company reported a cash and cash equivalents balance of $1.84 billion and deferred revenue of $2.16 billion, indicating robust future business growth [6] - The K12 business segment is expected to drive revenue growth, with a projected growth rate of approximately 20% for FY2026Q3 [8] Revenue and Profit Forecast - The company anticipates FY2026Q3 net revenue between $1.31 billion and $1.35 billion, representing a year-over-year increase of 11% to 14% [7] - Revenue projections for FY2026 to FY2028 are $5.48 billion, $6.11 billion, and $6.77 billion, respectively, with corresponding net profits of $492 million, $600 million, and $694 million [11][13]

Investment Rating - The report maintains an "Outperform" rating for Hutchmed (China) Limited with a target price of HK$38.11, reflecting a potential upside from the current price of HK$22.18 [2][25]. Core Insights - Hutchmed reported a total revenue of USD 549 million for FY25, a decrease of 13% year-on-year, with oncology/immunology combined revenue at USD 290 million, down 21% year-on-year. The decline was attributed to a high base effect from a previous milestone payment and a drop in domestic sales of key products [3][18]. - The management expects a recovery in sales for FY26, projecting oncology/immunology revenue between USD 330 million and USD 450 million, which includes potential income from licensing the ATTC platform [3][19]. - The company is focusing on the development of its Antibody-Targeted Toxin Conjugate (ATTC) platform, with two products currently in global clinical development [6][19]. Financial Performance - For FY25, Hutchmed's R&D expenses were USD 150 million, down 30% year-on-year, while SG&A expenses were USD 100 million, a decrease of 9% year-on-year. The net profit attributable to shareholders reached USD 460 million, boosted by a one-time gain from the sale of a subsidiary [3][18]. - The company had cash and cash equivalents of USD 1.37 billion at the end of FY25, indicating a strong cash position [3][18]. Product Performance - Fruquintinib (ex-China) sales reached USD 370 million, up 26% year-on-year, driven by growth in the Japanese market and improved reimbursement coverage in Europe. However, domestic sales of Fruquintinib (China) fell to USD 76.9 million, down 11% year-on-year, impacted by intensified competition [19][23]. - The report highlights that the sales of core products in China showed signs of improvement in the second half of FY25 compared to the first half, with Fruquintinib (China) revenue increasing by 29% quarter-on-quarter [19][23]. Clinical Development - HMPL-A251, a first-in-class ATTC targeting HER2, has shown promising anti-tumor activity comparable to existing therapies and is currently in a global Phase I/IIa clinical trial for advanced solid tumors [20][24]. - HMPL-A580, another ATTC candidate targeting EGFR, has also entered clinical development, with a global Phase I trial initiated in March 2026 [21][22]. Valuation - The revenue forecasts for FY26 and FY27 have been adjusted to USD 653 million and USD 699 million, respectively, reflecting the competitive landscape. The net profit forecasts for the same periods have been adjusted to USD 10 million and USD 32 million [9][25]. - The valuation is based on a DCF model with a WACC of 9.2% and a perpetual growth rate of 3.0%, leading to a target price of HK$38.11 per share [9][25].

Investment Rating - The report does not explicitly state an investment rating for SJM Holdings, but it highlights significant declines in revenue and EBITDA, indicating potential concerns for investors. Core Insights - SJM Holdings reported a net revenue of HKD 6.5 billion for 25Q4, a decrease of 13% year-on-year, and an adjusted EBITDA of HKD 0.67 billion, down 32.4% year-on-year, with an EBITDA margin of 10.3%, down 3 percentage points year-on-year [1][7][11]. - The closure of satellite casinos has negatively impacted the company's gross gaming revenue (GGR), which reached HKD 6.66 billion, down 11.6% year-on-year, and the growth rate was below the industry average of +15% [3][10]. - The company's market share in 25Q4 was 10.4%, down from 11.8% in 25Q3 and 13.5% in 24Q4, indicating a decline in competitive positioning [5][12]. Summary by Sections Financial Performance - In 25Q4, SJM Holdings' net revenue was HKD 6.5 billion, down 13% year-on-year and 7.6% quarter-on-quarter. The gaming and non-gaming segments contributed HKD 6.04 billion and HKD 0.46 billion, respectively, with declines of 13.2% and 10.9% year-on-year [2][8]. - The adjusted EBITDA for 25Q4 was HKD 0.67 billion, reflecting a 32.4% year-on-year decline and a 23.8% quarter-on-quarter decline, with a margin of 10.3% [4][11]. Market Dynamics - The closure of satellite casinos has led to a slowdown in the company's GGR growth, with significant declines in the GGR from VIP and mass market segments [3][10]. - The company has undertaken acquisitions and property upgrades to consolidate market share, including properties on the Macau Peninsula, which are expected to attract customers previously served by satellite casinos [5][12]. Operational Adjustments - SJM Holdings has been reallocating gaming tables and operational resources from closed satellite casinos to its self-operated properties, aiming to mitigate the impact of the closures [5][12]. - The company plans to gradually close its satellite casinos, with the first closure occurring at the end of July 2025, and the remaining closures concentrated in the fourth quarter of 2025 [4][11].

Investment Rating - The report maintains an "Outperform" rating for JD Logistics [5][8] Core Insights - The company's 2025 performance met expectations, with revenue of 217.1 billion RMB, a year-on-year increase of 18.8%, and an adjusted net profit of 7.71 billion RMB, a decrease of 2.6% [8] - JD Logistics is enhancing its integrated supply chain business, achieving a revenue of 116.2 billion RMB in this segment, which represents a 33% year-on-year growth [8] - The overseas business is expected to contribute significantly to profit growth in 2026, supported by investments in infrastructure and the expansion of its logistics network [8] - The express and freight segment is focusing on high-value time-sensitive products, leading to an optimization of the profit structure [8] - The profit forecast for 2026 and 2027 has been raised, with adjusted net profits expected to be 9.57 billion RMB and 11.09 billion RMB, respectively, reflecting year-on-year growth of 28.1% and 15.9% [8] Financial Data and Profit Forecast - Revenue projections for 2024 to 2028 are as follows: - 2024: 182.84 billion RMB - 2025: 217.15 billion RMB - 2026E: 261.35 billion RMB - 2027E: 301.94 billion RMB - 2028E: 343.14 billion RMB [4][9] - Adjusted net profit forecasts for the same period are: - 2024: 7.03 billion RMB - 2025: 7.47 billion RMB - 2026E: 9.57 billion RMB - 2027E: 11.09 billion RMB - 2028E: 12.76 billion RMB [4][9] - The expected earnings per share for 2026 is 1.43 RMB, with a projected price-to-earnings ratio of 8 [4][9]

Investment Rating - The report assigns a positive investment rating to JD Health, indicating strong performance and growth potential [4]. Core Insights - JD Health's performance in the second half of 2025 significantly exceeded expectations, with revenue growing by 28% year-on-year to 38.2 billion yuan and adjusted EBITDA increasing by 88% to 1.9 billion yuan [4]. - The company is expected to maintain revenue momentum into 2026, primarily driven by prescription drugs, with adjusted net profit growth projected to remain in the low single digits due to increased investments in O2O, offline pharmacies, and AI [4]. Summary by Sections Revenue Growth - Direct sales revenue increased by 28% year-on-year to 38.2 billion yuan in the second half of 2025, with pharmaceutical sales growing by 30% and nutritional products by 20% [5]. - The number of active users rose to 218 million, a 19% increase year-on-year, representing about 30% of JD's active buyers [5]. Platform and Advertising Revenue - Revenue from platforms, digital marketing, and other services grew by 34% year-on-year to 6.6 billion yuan, driven by increased digital marketing service fees and a rise in the number of advertisers [6]. Profitability - Adjusted EBITDA surged by 88% year-on-year, with a profit margin increase of 1.6 percentage points to 5% due to operational optimization and advertising growth [7]. - Adjusted net profit grew by 38% year-on-year, with a profit margin of 7.7%, reflecting a 0.6 percentage point increase [7]. Catalysts - Support from JD Group's traffic and revenue sharing from advertising, along with favorable policies in the internet and healthcare sectors, are seen as key catalysts for growth [8].

Investment Rating - The report maintains a positive outlook on Prada, indicating a strong start to 2026 but with mixed guidance for the year ahead [5][7]. Core Insights - Prada's sales and profitability for Q4 of FY2025 met expectations, with organic sales growth of +5% for Q4 and +7.8% for the full year, aligning with Visible Alpha's forecasts [6]. - The company faces potential headwinds from slowing growth in Miu Miu and dilution effects from Versace, which may impact the overall growth outlook [5][6]. - The strategic focus for 2026 includes optimizing channels and integrating Versace, with a plan to close more stores than open new ones [8]. Summary by Relevant Sections Financial Performance - For FY2025, Prada's Q4 organic sales growth was +5%, and full-year growth was +7.8%, consistent with market expectations [6]. - Retail sales growth for Q4 and the full year was +8% and +6% respectively, driven by same-store growth and low single-digit area growth [6]. - The EBIT margin for H2 and FY2025 was 23.7% and 23.2%, reflecting a decline due to Versace's dilution effect [6]. Market Outlook - The beginning of FY2026 shows strong performance from Prada, with robust sales during the Chinese New Year and stable performance in the U.S. market [7]. - Miu Miu is expected to see low single-digit growth in the first half of 2026, while Versace's sales are projected to decline in the mid to high single digits [7]. Strategic Initiatives - Prada plans to focus on the integration of Versace and channel optimization, with a significant emphasis on creative innovation under the new creative director Pieter Mulier [8]. - The company aims to stabilize the number of Miu Miu stores at 170-175 after adding 5-10 new locations [8]. Catalysts - Key catalysts for growth include the unexpected momentum of Miu Miu and Prada brands, benefiting from well-received designs and series releases, as well as improvements in consumer sentiment among key demographics [9].